Celestia Diagnostics develops lab tests and clinical bioinformatics systems to aid in the diagnosis and treatment of chronic complex conditions such as Long COVID, ME/CFS, and POTS.
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
Benilight
Illuminating the Future of Brain Health: Benilight at BioUSA 2026 The Vision: Beyond Light, Toward Neural Recovery In a world grappling with a growing mental health crisis, Benilight is redefining the boundaries of non-invasive therapy. We don’t just provide devices; we provide a Neural Recovery Ecosystem. At BioUSA 2026, we are proud to unveil the next evolution of our flagship technology: the iLED Pro, now integrated with an AI-powered Medical Doctor App, specifically targeting Post-Traumatic Stress Disorder (PTSD). Core Innovation: The iLED Pro & AI Synergy The iLED Pro is an FDA-listed, professional-grade photobiomodulation (PBM) device. While it has already set industry standards for pain management and tissue recovery, our focus has shifted toward the final frontier: The Brain. Triple-Wavelength Precision: Utilizing a combination of 660nm (Red), 850nm (NIR), and 940nm (NIR), the iLED Pro penetrates deep into cortical tissues to stimulate mitochondrial function and ATP production. Ethical Engineering: Our flexible LED pads are built for the rigors of clinical and home use, tested to withstand over 300,000 bends without losing intensity or integrity. The AI Doctor Integration: Our new AI-driven application acts as a digital clinician. It monitors patient progress, optimizes light dosages based on neurological biofeedback, and provides real-time data to healthcare providers, making the iLED Pro a truly “smart” medical asset. The Indication: A New Hope for PTSD Post-Traumatic Stress Disorder remains one of the most difficult conditions to treat without heavy reliance on pharmaceuticals. Benilight is currently pursuing clinical evidence and regulatory pathways for a PTSD indication, leveraging PBM’s ability to: – Reduce Neuro-inflammation: Calming the physiological “storm” associated with trauma. – Enhance Connectivity: Improving functional connectivity in brain regions impacted by TBI and PTSD. – Optimize Sleep & Circadian Rhythms: Directly addressing the insomnia and night terrors that plague PTSD survivors. Strategic Opportunities for Partners We are at BioUSA to meet the visionaries who will help us scale this life-changing technology globally. Our Value Propositions : – Participation in a high-growth Digital Health firm bridging the gap between MedTech hardware and AI software. – Exclusive access to a versatile, FDA-listed device with a massive untapped market in mental health and sports medicine. – Collaborative opportunities to integrate our LED technology into broader telehealth platforms or specialized clinical chains. Why Visit the Benilight Booth? – Live Demos: Experience the soothing, deep-penetration technology of the iLED Pro firsthand. – The AI Interface: See how our AI App transforms a light therapy device into a sophisticated diagnostic and treatment tool. – Clinical Insights: Speak with our leadership team, including CEO Yosik Song and CTO Dr. Sungkyoo Lim, who brings over 30 years of light-science expertise to the table. Meet Us in San Diego – Event: Bio International Convention (BioUSA) 2026 – Location: San Diego Convention Center – Dates: June 22 – 25, 2026 – Focus: AI-Powered Photobiomodulation for PTSD & Brain Health | Benilight has developed LED medical devices and healthcare products utilizing red LEDs and near-infrared (NIR) LEDs. Our company has conducted extensive research on the effects of LED light on the skin. These devices have been listed as Class II medical devices by the US FDA for pain relief and the enhancement of blood circulation.
Acer Inc.
Acer Inc. was founded in 1976 by Stan Shih and is a Taiwan-based global technology company with operations in over 160 countries. Building on its strong foundation in computing and data technologies, Acer has strategically expanded into the biomedical field to develop a next-generation RNA therapeutics platform. Since 2018, the company has focused on personalized cancer vaccines, powered by proprietary AI models for high-precision neoantigen prediction. This AI-driven engine enables rapid identification of clinically relevant targets, significantly accelerating and improving the design of individualized immunotherapies. In 2021, Acer established its mRNA-LNP platform and has since developed a proprietary ionizable lipid, AIL-111, engineered for high delivery efficiency and favorable in vivo performance. This platform enables robust mRNA delivery and serves as the foundation for multiple therapeutic applications. Leveraging this core capability, Acer is advancing a targeted LNP (tLNP) platform for cell-specific delivery, including in vivo CAR-T cell generation, where mRNA is directly delivered to T cells within the body to induce transient CAR expression. This approach has the potential to simplify manufacturing, reduce cost, and improve accessibility compared to conventional ex vivo cell therapies. By integrating AI-driven antigen discovery, proprietary LNP delivery technology, and in vivo cell engineering, Acer is building a scalable and modular platform for next-generation RNA medicines. The company aims to become a key innovator at the intersection of digital technology and biopharmaceutical development, enabling transformative therapies for cancer and beyond.
AB DigiHealth Inc.
AB DigiHealth Inc. stands as a pioneering, modern core laboratory dedicated to advancing genomic research. Originating as a startup from Center for Genomic Medicine, National Cheng Kung University in Taiwan, our mission is to bridge the gap between scientific discoveries and clinical applications, providing a comprehensive solution for maternal-fetal precision medicine to the world. Harnessing state-of-the-art Next-Generation Sequencing (NGS) technology, advanced bioinformatics, and AI predictive algorithms, our goal is to usher prenatal genetic testing into a new era. As guardians of maternal-fetal health, we endeavor to create an efficient, empowering digital solution that leverages cloud-based NGS analytics pipelines and AI-based companion diagnosis. Our vision is to establish a next-generation healthcare system characterized by high accuracy, enhancing operational efficiency in laboratories and clinics.